De­spite flop­ping piv­otal tri­al, No­var­tis' En­tresto will face ad­comm fir­ing line for holy grail heart fail­ure pa­tients

No­var­tis had big ideas for its heart-fail­ure mar­ket leader En­tresto in a high­ly sought-af­ter pa­tient pop­u­la­tion be­fore a Phase III flop de­railed its plans. But …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.